• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Prelude Therapeutics, Inc.

    Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces $25 Million Private Placement
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics To Participate in Jefferies Healthcare Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces Pricing of Public Offering
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces Launch of Proposed Public Offering
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Tickers PRLD
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.